Non-myeloablative allogeneic stem cell transplantation for metastatic renal cell carcinoma.
Between 1999 and 2004, 11 patients with metastatic renal cell carcinoma (RCC) underwent non-myeloablative stem cell transplantation (NST) with conditioning using fludarabine-based regimens in two institutions of Korea. Among 11 patients, only one patient showed partial response (response rate: 9%), three showed stable disease, and six progressive disease. Three patients developed acute graft-versus-host disease (GVHD), and among them, one developed grade III acute GVHD which caused early death at day 60 after transplantation, and this patient showed partial response at day 30. Six patients developed chronic GVHD, three limited, and three extensive GVHD, respectively. Survival after one yr was 18% in transplanted patients. Median overall survival for entire cohort was 4.3 months. Eight patients died from progressive disease and three (27%) from treatment-related mortality. Only one patient survived 51.2 months after NST with slowly progressive disease. This patient received donor lymphocyte infusion three times after NST and achieved complete donor chimerism. NST does not lead to durable response and prolonged overall survival in the majority of patients with RCC in our series.
Yun
Tak
T
Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.
Lee
Keun-Wook
KW
Song
Eun-Gi
EG
Na
Im-Il
II
Shin
Hyun-Chun
HC
Yoon
Sung-Soo
SS
Park
Seon-Yang
SY
Kim
Byoung-Kook
BK
Lee
Jung-Hee
JH
Choi
Seong-Jun
SJ
Lee
Je-Hwan
JH
Lee
Kyoo-Hyung
KH
D000328:Adult; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000401:mortality / Q000601:surgery*; D046528:Chimerism; D018450:Disease Progression; D005260:Female; D006086:Graft vs Host Disease; D006801:Humans; D007167:Immunotherapy; D007680:Kidney Neoplasms / Q000276:immunology / Q000401:mortality / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists; D033581:Stem Cell Transplantation; D019172:Transplantation Conditioning
D019653:Myeloablative Agonists